Sternberg, M.D., Kurt Miller, M.D., Ronald de Wit, M.D., Peter Mulders, M.D., Ph.D., Kim N. Chi, M.D., Neal D. Shore, M.D., Andrew J. Armstrong, M.D., Thomas W. Flaig, M.D.D., Ph.D., Paul Mainwaring, M.D., Tag Fleming, M.D., John D. Hainsworth, M.D., Mohammad Hirmand, M.D., Bryan Selby, M.S., Lynn Seely, M.D., and Johann S. De Bono, M.B., Ch.B., Ph.D. For the AFFIRM Investigators: Elevated Survival with Enzalutamide in Prostate Malignancy after Chemotherapy Prostate cancer can be an androgen-dependent disease that initially responds but later becomes resistant to established therapies that reduce circulating testosterone amounts or inhibit androgen binding to the androgen receptor.1-4 Reactivation of the disease despite castrate levels of testosterone represents a changeover to the lethal phenotype of castration-resistant prostate cancer.5,6 This state once was called androgen-independent or hormone-refractory prostate cancers but is now proven to be powered by androgen-receptor signaling, partly due to overexpression of the androgen receptor itself.7,8 In preclinical models of prostate cancer, androgen-receptor overexpression shortens the period of tumor latency and confers resistance to conventional antiandrogen agents, such as bicalutamide.Desperate to vaccinate more men, Walgreens announces free sex with every flu shot. Present cards fly off the shelves. Senator X discovered to become a dirty, corrupt liar protecting the continuing businesses interests of company Y which supported his campaign. Health authorities demand that meals X become irradiated to eliminate pathogen Y. Big oil companies trash the surroundings. And there you have it! Those will be the main headlines you’ll see through 2011. Just replace the X and Y with whatever fact is being presented on that particular day.